Business Valuation Zone

Freshfields-Led Novartis Inks $1.75B Cancer Drug Co. Buyout

Law 360 M&A

MAY 2, 2024

Novartis AG said Thursday it has agreed to buy U.S. radiopharmaceutical company Mariana Oncology in a transaction worth up to $1.75 billion, as the Swiss pharmaceutical giant moves to bolster its precision nuclear medicine portfolio.

US Greenlights Novartis' $2.9B MorphoSys Takeover

Law 360 M&A

MARCH 22, 2024

Germany's MorphoSys AG said Friday it has received U.S. antitrust clearance for the biopharmaceutical company's planned $2.9 billion sale to Swiss Pharma giant Novartis AG, a development that clears the final regulatory hurdle needed before closing the deal.

Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?

Benzinga

JANUARY 8, 2024

Cytokinetics Inc (NASDAQ: CYTK ) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS ). The Wall Street Journal noted that Novartis is nearing the final stages of acquiring Cytokinetics, a company focused on developing heart disease drugs.

Equity

Equity Marketability

Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition

Benzinga

JANUARY 11, 2024

Novartis AG (NYSE: NVS ) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK ) acquisition, dealing a blow to the potential deal with the promising heart-drug developer.

Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution

Benzinga

AUGUST 18, 2023

Novartis AG (NYSE: NVS ) said the planned spin-off of its Sandoz unit is expected to occur on October 4 , ending an era for the Swiss pharmaceutical giant in which generic and prescription drugs businesses coexisted. In October 2021, Novartis commenced a strategic review exploring all options.

Marketability

Novartis To Spinoff Sandoz Business To Create #1 European Generics Company

Benzinga

AUGUST 25, 2022

Novartis AG (NYSE: NVS ) plans to spin off Sandoz, its generics and biosimilars division, into a new publicly traded standalone company. Related: Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings. Full story available on Benzinga.com.

States Ask To Block Sandoz Spinoff Over Price-Fixing Claims

Law 360 M&A

SEPTEMBER 29, 2023

State enforcers and others have asked a Pennsylvania federal court to halt Novartis AG's planned spinoff of its Sandoz unit, saying the move could stop them from recovering overcharges from the company for a sprawling conspiracy to fix generic drug prices.

Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations

Benzinga

JUNE 8, 2023

Novartis AG's (NYSE: NVS ) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its parent company later this year.

Marketability

Novartis To Spin Off $9.6B Sandoz Generic Drugs Biz

Law 360 M&A

AUGUST 25, 2022

Swiss-American pharmaceuticals giant Novartis AG said Thursday that it plans to separate its Sandoz generic drugs division from its core business of developing innovative medicines to form a standalone publicly traded company through a 100% spinoff.

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'

Benzinga

APRIL 7, 2023

Read on for the full interview in which Shah discusses Rocket's stock movement, the lessons he learned from his previous roles at Eli Lilly And Co (NYSE: LLY ) and Novartis AG (NYSE: NVS ), whether future M&A plans are in the works and why World Health Day , which started in 1950 and is commemorated on April 7, is still a noteworthy event.

Marketability

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG

Benzinga

JUNE 11, 2023

Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 The transaction has been unanimously approved by the Boards of Directors of both companies. "We

Equity

Coherus to Acquire Surface Oncology

Benzinga

JUNE 16, 2023

The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2023. and CAMBRIDGE, Mass., and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. Coherus, NASDAQ: CHRS ) and Surface Oncology, Inc.

Marketability

Coherus to Acquire Surface Oncology

Benzinga

JUNE 16, 2023

The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2023. and CAMBRIDGE, Mass., and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. Coherus, NASDAQ: CHRS ) and Surface Oncology, Inc.

Marketability

Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14

Benzinga

OCTOBER 14, 2022

Twitter said in a court filing released Thursday that Musk’s attorneys claimed “investigative privilege” while refusing to hand over material sought by the social media company. Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug. Stellantis Unit Agrees To Pay $5.6M will pay $5.6

Technology

Technology Marketability

Business Valuation Zone

Freshfields-Led Novartis Inks $1.75B Cancer Drug Co. Buyout

US Greenlights Novartis' $2.9B MorphoSys Takeover

Trending Sources

Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?

Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition

Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution

Novartis To Spinoff Sandoz Business To Create #1 European Generics Company

States Ask To Block Sandoz Spinoff Over Price-Fixing Claims

Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations

Novartis To Spin Off $9.6B Sandoz Generic Drugs Biz

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG

Coherus to Acquire Surface Oncology

Coherus to Acquire Surface Oncology

Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14

Stay Connected